ToolGen (KOSDAQ: 199800; CEO Jong-sang Ryu), a leader in genome editing technology, announced that the United States Patent ...

Scientists used CRISPR to disable the NRF2 gene, restoring chemotherapy sensitivity in lung cancer cells and slowing tumor ...

IGIB and the Serum Institute of India aims to make sickle cell treatment accessible to India's tribal communities, where the ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, ...

A new study shows that neurons repair CRISPR-Cas9 cuts in unique, highly predictable ways, unlike dividing cells. Researchers ...

In a major leap for Atmanirbhar Bharat and India’s genomic medicine capabilities, the government on Wednesday launched the ...

USA News Group News Commentary ? The autologous cell therapy market surpassed $10.1 billion in 2025 as biotechnology companies race to commercialize therapies that read, replace, and rewrite cellular ...

CRISPR has turned a simple fungus into a fast-growing, meat-like protein source with impressively low environmental impact.

Launching the therapy, Dr. Jitendra Singh declared that India has officially begun its decisive march toward a Sickle ...

India has launched BIRSA 101, the nation’s first indigenous CRISPR-based gene therapy for Sickle Cell Disease, marking a ...

Study shows gene editing restores drug sensitivity by targeting NRF2, with potential across multiple tumor types.